(Q80829565)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Sharyn D. Baker

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

V Gregorc

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

A Spreafico

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

G Cusatis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

V Ludovini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

R G Ingersoll

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

S Marsh

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

S M Steinberg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

M G Viganò

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

D Ghio

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

E Villa

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

A Sparreboom

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

22 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

3 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

477-484

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17713473%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100320

3 January 2020

exact match

0 references

cites work

Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Where next for gefitinib in patients with lung cancer?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021

Statistical aspects of prognostic factor studies in oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100320

7 January 2021